Biologic Exclusivity Provision In USMCA Is Boon To Generics Industry; BIO Is 'Tremendously Worried'
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
You may also be interested in...
USMCA is looking more and more like a win for generic firms, who hope it will be template for future trade agreements.
Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.
Biologics exclusivity remains a contentious issue as US Trade Representative and House Democrats begin discussions on the trade pact with Mexico and Canada.